isoniazid has been researched along with 4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Bifani, P; Camacho, LR; Chatterjee, AK; Diagana, TT; Dick, T; Goh, A; Herve, M; Jiricek, J; Kondreddi, RR; Kuhen, K; Lakshminarayana, SB; Ma, NL; Manjunatha, UH; Rao, R; Rao, SP; Smith, PW | 1 |
Bishai, WR; Guo, H; Kozikowski, AP; Lun, S; Merenbloom, B; Onajole, OK; Stec, J; Vistoli, G | 1 |
Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
1 review(s) available for isoniazid and 4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide
Article | Year |
---|---|
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
2 other study(ies) available for isoniazid and 4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide
Article | Year |
---|---|
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; Humans; Indoles; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Rats; Solubility; Structure-Activity Relationship; Tuberculosis | 2013 |
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Humans; Indoles; Membrane Transport Proteins; Mice, Inbred BALB C; Microbial Sensitivity Tests; Models, Molecular; Molecular Docking Simulation; Molecular Targeted Therapy; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |